USFDA approves Sun Pharmaceutical's ANDA to market Rilutek tablets

NewsGuard 100/100 Score
Sep 29 2010

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Sanofi Aventis's Rilutek® tablets 50 mg.

These generic Riluzole Hydrochloride tablets contain Riluzole Hydrochloride 50 mg. Riluzole Hydrochloride tablets are indicated in the treatment of amyotrophic lateral sclerosis.

Rilutek has annual sale of approximately $ 50 million in the US.

Source:

: Sun Pharmaceutical Industries Ltd.

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status
New urine-based test improves identification of high-grade prostate cancer
Study highlights growing burden of neurological disorders worldwide
Common HIV drugs linked to reduced Alzheimer's disease risk
SickKids study offers new path for pediatric rare disease clinical trials
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain
Study highlights global fertility decline and its implications for the future
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Lancet Commission predicts sharp increase in global prostate cancer cases